Updates are available Correction dated 2023-09-03

Article History

Received: 27 July 2023

Accepted: 30 July 2023

First Online: 19 August 2023

Change Date: 3 September 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1245/s10434-023-14252-2

Disclosure

: Jennifer A. Wargo reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol Myers Squibb; serves as a consultant and/or advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Merck, Biothera Pharmaceuticals, Microbiome DX and Micronoma; and receives research support from GlaxoSmithKline, Roche/Genentech, Bristol Myers Squibb and Novartis. Merrick I. Ross reports consultant compensation from Merck and travel expense support from Merck for Advisory Board participation. Ashley M. Holder has no conflicts of interest to declare.

Free to read: This content has been made available to all.